Needham & Company LLC Forecasts Strong Price Appreciation for Globus Medical (NYSE:GMED) Stock

Globus Medical (NYSE:GMED) had its price objective boosted by Needham & Company LLC from $112.00 to $114.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the medical device company’s stock. Needham & Company LLC’s price target would indicate a potential upside of 17.91% from the stock’s current price.

Several other equities research analysts have also recently weighed in on the company. BTIG Research reissued a “neutral” rating on shares of Globus Medical in a research report on Tuesday, December 30th. Piper Sandler reissued an “overweight” rating and issued a $115.00 price target (up from $90.00) on shares of Globus Medical in a report on Thursday, January 8th. Morgan Stanley boosted their price objective on shares of Globus Medical from $70.00 to $100.00 and gave the stock an “overweight” rating in a report on Tuesday, December 2nd. Stifel Nicolaus started coverage on shares of Globus Medical in a research note on Tuesday, October 28th. They issued a “hold” rating and a $64.00 target price for the company. Finally, Truist Financial reissued a “buy” rating and set a $105.00 target price (up from $93.00) on shares of Globus Medical in a research report on Tuesday, November 18th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, Globus Medical presently has a consensus rating of “Moderate Buy” and an average target price of $104.36.

Globus Medical Stock Performance

GMED opened at $96.68 on Wednesday. The company has a market cap of $12.94 billion, a PE ratio of 24.54, a price-to-earnings-growth ratio of 1.37 and a beta of 1.06. The stock has a 50-day moving average of $90.52 and a 200-day moving average of $76.13. Globus Medical has a 52-week low of $51.79 and a 52-week high of $101.40.

Globus Medical (NYSE:GMED) last issued its quarterly earnings data on Tuesday, February 24th. The medical device company reported $1.28 earnings per share for the quarter, beating analysts’ consensus estimates of $1.06 by $0.22. The business had revenue of $826.42 million for the quarter, compared to the consensus estimate of $803.29 million. Globus Medical had a return on equity of 12.57% and a net margin of 18.30%.The firm’s revenue was up 25.7% compared to the same quarter last year. During the same period last year, the business earned $0.84 EPS. On average, research analysts predict that Globus Medical will post 3.44 earnings per share for the current year.

Insider Activity at Globus Medical

In related news, Director Leslie V. Norwalk sold 2,000 shares of the stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $101.10, for a total value of $202,200.00. Following the completion of the transaction, the director owned 10,419 shares of the company’s stock, valued at $1,053,360.90. This represents a 16.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Kelly Huller sold 10,000 shares of the firm’s stock in a transaction dated Thursday, February 12th. The stock was sold at an average price of $87.67, for a total transaction of $876,700.00. The SEC filing for this sale provides additional information. Insiders have sold a total of 34,136 shares of company stock valued at $3,111,033 over the last quarter. 18.51% of the stock is owned by company insiders.

Institutional Trading of Globus Medical

Institutional investors have recently bought and sold shares of the stock. AQR Capital Management LLC raised its stake in Globus Medical by 45.9% during the first quarter. AQR Capital Management LLC now owns 22,510 shares of the medical device company’s stock worth $1,622,000 after acquiring an additional 7,086 shares in the last quarter. Integrated Wealth Concepts LLC grew its holdings in shares of Globus Medical by 33.0% in the 1st quarter. Integrated Wealth Concepts LLC now owns 4,375 shares of the medical device company’s stock worth $320,000 after purchasing an additional 1,085 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Globus Medical by 38.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,649 shares of the medical device company’s stock worth $2,228,000 after purchasing an additional 8,540 shares during the last quarter. Jones Financial Companies Lllp increased its position in shares of Globus Medical by 237.3% during the 1st quarter. Jones Financial Companies Lllp now owns 850 shares of the medical device company’s stock worth $62,000 after purchasing an additional 598 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Globus Medical by 8.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 347,527 shares of the medical device company’s stock valued at $25,439,000 after purchasing an additional 28,027 shares during the last quarter. Institutional investors and hedge funds own 95.16% of the company’s stock.

Globus Medical News Summary

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Barclays raised its price target to $123 and kept an overweight rating (largest upside among recent lifts), signaling stronger revenue/earnings confidence. Globus Medical (NYSE:GMED) Given New $123.00 Price Target at Barclays
• Positive Sentiment: Needham increased its target to $114 and reiterated a Buy rating, reflecting upgraded estimates and constructive commentary on spine & robotics growth. Globus Medical (NYSE:GMED) Given New $114.00 Price Target at Needham & Company LLC
• Positive Sentiment: Wells Fargo lifted its target to $104 and moved to an Overweight rating, adding further analyst buying conviction. Benzinga
• Positive Sentiment: Multiple sell-side analysts (TD Cowen, Morgan Stanley, Needham commentary on TipRanks) reiterated Buy/Overweight calls and cited strengthening U.S. spine momentum, margin expansion, and accretion from M&A/robotics as durable catalysts. TD Cowen/TipRanks coverage
• Positive Sentiment: Q4 results beat consensus: EPS of $1.28 vs. ~$1.06 est and revenue ahead of estimates — supporting upward revisions to 2026 EPS and showing double-digit revenue growth year-over-year. Zacks: GMED Surpasses Q4 Earnings and Revenue Estimates
• Positive Sentiment: Company Q4 earnings call highlighted profitable growth and execution on margin expansion and robotics momentum — reinforcing analyst optimism. TipRanks: Earnings Call Shows Profitable Growth
• Neutral Sentiment: Full Q4 earnings call transcript published for investor review (useful for detail but informational rather than a new catalyst). Seeking Alpha: Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Analyst and media write-ups (Zacks/TipRanks) provide deeper metric analysis; helpful for modelling but largely reiterative of the beat and guidance commentary. Zacks: Key Metrics on GMED Q4

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.